Quantcast
Last updated on April 21, 2014 at 5:21 EDT

Latest Multiple myeloma Stories

2012-11-05 12:25:58

BOULDER, Colo., Nov. 5, 2012 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that data will be presented on two drug candidates, ARRY-520, a KSP inhibitor, and ARRY-614, a dual p38/Tie2 inhibitor, at the 2012 Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia. Array will also hold a conference call today, Monday, November 5, 2012 at 4:30 p.m. ET, to review the abstracts. The call-in details are provided below. (Logo:...

2012-10-27 23:20:06

NORWALK, Conn., Oct. 28, 2012 /PRNewswire/ -- The Multiple Myeloma Research Foundation (MMRF) joined forces with some of the biggest names in the music industry in its ongoing fight against cancer at the 15(th) Anniversary MMRF Fall Gala last night. All funds raised at this special event, which took place at the Hyatt Regency Greenwich in Old Greenwich, CT, will support the development of life-extending treatments for multiple myeloma, an incurable blood cancer. The event, co-chaired by...

2012-10-16 04:03:59

Mitch Vazquez, an active benefactor, now extends his support to the Advance Cancer Research philanthropy that makes effort to accelerate cure for the people suffering from Myeloma. As an active donator he helps this cause to conduct researches in bringing new treatments to patients. He offers substantial gifts to this cause that is dedicated to finding cures and treatments for certain types of cancer. New York, NY (PRWEB) October 15, 2012 Mitch Vazquez, an active benefactor, now extends his...

2012-10-08 07:24:18

BALTIMORE, Oct. 8, 2012 /PRNewswire/ -- Gliknik Inc., a privately held biopharmaceuticals company creating new therapies for cancer and immune / inflammatory disorders, today announced that it has raised $4.9 million in Series B Financing. Baxter Ventures, an initiative created in 2011 by Baxter International Inc., led the Series B raise and is joined by existing investors. With the funding, Gliknik will further advance towards the clinic its IVIG-mimetic lead compound, GL-2045,...

2012-09-27 23:03:53

Mitch Vazquez, an enthusiastic philanthropic donor offers aid to the Advance Cancer Research philanthropy. He is an active benefactor helping number of regional causes in their act to make the world a better place for some underprivileged people. (PRWEB) September 27, 2012 Mitch Vazquez, an enthusiastic philanthropic donor offers aid to the Advance Cancer Research philanthropy. He is an active benefactor helping number of regional causes in their act to make the world a better place for...

2012-09-20 06:31:55

CAMBRIDGE, Mass., Sept. 20, 2012 /PRNewswire/ -- Eutropics Pharmaceuticals has signed a $1.5M phase 2 contract with the National Cancer Institute Small Business Initiative Research (NCI-SBIR) to commercially develop its proprietary diagnostic assay for personalized medicine approaches in Multiple Myeloma (MM) patient management. The award follows a highly successful phase 1 contract that demonstrated the commercial potential for the core technology called BH3 profiling. Eutropics holds an...

2012-09-18 18:40:31

In the first clinical trial to demonstrate an effective treatment for constant, disabling cough among people with idiopathic pulmonary fibrosis (IPF), researchers at the Johns Hopkins University School of Medicine found that taking thalidomide significantly reduced the cough and improved quality of life. Results of their study are scheduled to be published in the Annals of Internal Medicine on Sept. 18 in an article titled "Thalidomide for the Treatment of Cough in Idiopathic Pulmonary...

2012-09-12 02:29:20

NEW YORK, Sept. 12, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API) announced today that Geraldine Henwood, an experienced biopharmaceutical executive, joined the Company's management team in the consultative capacity of Chief Development Officer, Iomab-B. Ms. Henwood will spearhead efforts on further development of its clinical stage Iomab-B drug candidate. Iomab-B is a monoclonal antibody construct in-licensed by API from Fred Hutchinson Cancer Research Center in Seattle. It is...

2012-08-23 02:24:26

WHITE PLAINS, N.Y., Aug. 23, 2012 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced the awarding of 20 grants representing a total investment of $12 million to tackle four areas of high unmet medical need in the blood cancers. In response to requests for proposals from researchers in these four critical areas, LLS is awarding these grants under its Translational Research Program, an initiative designed to help accelerate the movement of promising...

2012-08-21 06:27:17

CLEVELAND, Aug. 21, 2012 /PRNewswire/ -- Arteriocyte, a leading clinical stage biotechnology company developing cellular based therapies to treat human diseases, announced today the successful award of another grant by the National Institute of Health for the use of the NANEX(TM) platform in Hematopoietic Reconstitution Using Ex Vivo Expanded Umbilical Cord Blood CD34+ Stem Cells. The funding will enable development of the company's NANEX(TM) platform for use in stem cell transplants, a...